Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.
MKS Instruments Analysts Await Elaboration On Ransomware Impact Post Q4 Results
Benchmark analyst Mark Miller had a Hold rating on MKS Instruments, Inc (NASDAQ:MKSI). For its 4Q22, MKS reported adjusted EPS of $2.00…
